Floatz logo

Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes

Epstein-Barr Virus-Related Tumor

Atara BiotherapeuticsCell therapyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Epstein-Barr Virus-Related Tumor cohort.

Asset / SponsorPhaseRating
Tabelecleucel
Atara Biotherapeutics
Phase 2B
Ebv-Specific T Cells: B
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Avelumab
Yonsei University
Phase 2CCC
Ebv Mrna Vaccine
Sun Yat-sen University
Phase 1CC
AS01 COMPONENT QS-21
Ohio State University Comprehensive Cancer Center
Phase 1NR

Same molecule, other indications

Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes is also rated in:

post-transplant lymphoproliferative diseaseDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →
Hodgkins lymphomaDormant
CC
Indicative · Phase 1
43 / 100
View asset →
non-Hodgkin lymphomaDormant
CC
Indicative · Phase 1
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →